[Progress in the treatment of secondary hyperparathyroidism. Role of calcimimetics].
Calcium-phosphate balance abnormalities, present in chronic renal failure since its early stages, are responsible for their negative impact on bones and cardiovascular system which increases patients morbidity and mortality. Phosphate retention, the strong stimulator of PTH secretion, plays the main role in calcium-phosphate disturbances. The present paper reviews clinical experience with currently available phosphate binders and therapeutic strategies used in the treatment of secondary hyperparathyroidism. Special attention was paid to the new group of drugs namely calcimimetics, with emphasis on the first registered drug from this group cinacalcet. Mechanism of its' action, influence of the drug on calcium-phosphate balance parameters, safety profile, as well as the most frequent adverse effects are discussed in the present review.
Sułowicz
Władysław
W
Katedra i Klinika Nefrologii Collegium Medicum, Uniwersytetu Jagiellońskiego w Krakowie.
D002118:Calcium / Q000097:blood; D000069449:Cinacalcet; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D009281:Naphthalenes / Q000494:pharmacology / Q000627:therapeutic use*; D010281:Parathyroid Hormone / Q000378:metabolism; D010710:Phosphates / Q000097:blood; D044169:Receptors, Calcium-Sensing / Q000187:drug effects* / Q000378:metabolism; D006435:Renal Dialysis
D009281:Naphthalenes; D010281:Parathyroid Hormone; D010710:Phosphates; D044169:Receptors, Calcium-Sensing; D002118:Calcium; D000069449:Cinacalcet